Page last updated: 2024-10-28

fasudil and Liver Diseases

fasudil has been researched along with Liver Diseases in 2 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Liver Diseases: Pathological processes of the LIVER.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Thorlacius, K1
Slotta, JE1
Laschke, MW1
Wang, Y1
Menger, MD1
Jeppsson, B1
Thorlacius, H1
Ikeda, H1
Kume, Y1
Tejima, K1
Tomiya, T1
Nishikawa, T1
Watanabe, N1
Ohtomo, N1
Arai, M1
Arai, C1
Omata, M1
Fujiwara, K1
Yatomi, Y1

Other Studies

2 other studies available for fasudil and Liver Diseases

ArticleYear
Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury.
    Journal of leukocyte biology, 2006, Volume: 79, Issue:5

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Apoptosis; Cell Communication; Chemo

2006
Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats.
    American journal of physiology. Gastrointestinal and liver physiology, 2007, Volume: 293, Issue:4

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Androstadienes; Animals; Apoptosis; Carbon Tetrachlor

2007